AGAVE-201 Trial Review

Opinion
Video

A hematologist provides an overview of the AGAVE-201 trial investigating axatilimab in patients with chronic graft-vs-host disease.

Video content above is prompted by the following questions:

  • Please provide an overview of the AGAVE-201 trial, including its design, patient population, and key endpoints.
    • What were the primary and secondary endpoints of the AGAVE-201 trial, and how were they assessed?
    • How did the trial evaluate the efficacy, safety, and tolerability of different dosing regimens of axatilimab in patients with recurrent or refractory active chronic GVHD?
Recent Videos
Solly Chedid, MD, and Jamie Koprivnikar, MD
Solly Chedid, MD, and Jamie Koprivnikar, MD
Related Content